After a rocky decades-long journey, Takeda’s CMV drug gets FDA OK

Nicole DeFeudis

Editor

After a wild two-decade ride, the FDA has approved Takeda’s antiviral maribavir — now marketed as Livtencity — for cytomegalovirus, one of the most common viral infections …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After a rocky decades-long journey, Takeda’s CMV drug gets FDA OK

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Af­ter a rocky decades-long jour­ney, Take­da’s CMV drug gets FDA OK

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After a rocky decades-long journey, Takeda’s CMV drug gets FDA OK